Correct. I don't think many people realize that we, the shareholders, are not the audience. Nor are hedge fund managers or short sellers or hack journalists. We're all free to form our opinion and the share price will bounce around up and down as we all duke it out over whether the data is good or cherry picked, but ultimately the medical community will decide Blarcamesine's value and the rest of us will act accordingly.
Market Data 
Markets 
AI
